application): Low molecular peptides are ligands for a number of types of receptors. Delivery of peptides by an intranasal route would circumvent the problems of administering them by injection. This application is designed to 1) develop an intranasal formulation of Melanotan-II (MT-II), an agonist for melanocortin receptors, 2) study the properties of the formulation, and 3) study the bioavailability of the agent when delivered by intranasal system. Melanotan-II has potential as an agent to induce weight loss from suppression of appetite and to enhance sexual activity (erectile function). This approach toward formulating peptides for intranasal delivery may be useful as a general method to produce and deliver peptide therapeutic agents for a wide range of needs.

Proposed Commercial Applications

Melanotan-II has potential as an agent to induce weight loss from suppression of appetite and to enhance sexual activity (erectile function).

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Small Business Innovation Research Grants (SBIR) - Phase I (R43)
Project #
1R43GM060144-01
Application #
6017999
Study Section
Special Emphasis Panel (ZRG1-SSS-Z (01))
Program Officer
Hyde, James F
Project Start
1999-09-15
Project End
2000-03-14
Budget Start
1999-09-15
Budget End
2000-03-14
Support Year
1
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Palatin Technologies, Inc.
Department
Type
DUNS #
City
Cranbury
State
NJ
Country
United States
Zip Code
08512